Form 4: Corcept Therapeutics Executive Sells Shares
SEC Form 4 Filing
Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, sold 3,101 shares of common stock at $35.71 per share on August 26, 2024.
Summary
- Gary Charles Robb, the Chief Business Officer of Corcept Therapeutics, filed a Form 4 with the SEC.
- On August 26, 2024, Robb sold 3,101 shares of Corcept Therapeutics common stock at a price of $35.71 per share.
- Following the transaction, Robb directly owns 23,190 shares, which includes shares underlying unvested restricted stock awards.
- Robb also indirectly owns shares through custodial accounts for his child.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of an insider stock sale. The sale itself doesn't necessarily indicate a positive or negative outlook.
Industry Context
This filing is a routine disclosure of insider trading activity. It's important to monitor such filings to understand management's perspective on the company's stock.
Stakeholder Impact
- The stock sale could have a minor impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 09/01/2023 | Grant date of 500 shares underlying unvested restricted stock awards. |
| 12/01/2023 | Grant date of 638 shares underlying unvested restricted stock awards. |
| 03/01/2024 | Grant date of 697 shares underlying unvested restricted stock awards. |
| 06/01/2024 | Grant date of 1,818 shares underlying unvested restricted stock awards. |
| 08/26/2024 | Date of stock sale. |
| 08/28/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.